Pharmacogenomics of statin therapy: any new insights in efficacy or safety?

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?

PURPOSE OF REVIEW: To examine the current evidence concerning the effects of genetic variation on statin-related low-density lipoprotein cholesterol reductions, clinical efficacy, and adverse events and the relevance for patient care. RECENT FINDINGS: Recent years have seen the emergence of large-sc...

Descripció completa

Dades bibliogràfiques
Autors principals:	Hopewell, J, Reith, C, Armitage, J
Format:	Journal article
Idioma:	English
Publicat:	Lippincott Williams and Wilkins 2014

Ítems similars

Interpretation of the evidence for the efficacy and safety of statin therapy
per: Collins, R, et al.
Publicat: (2016)

Safety and efficacy of statins - Authors' reply
per: Collins, R, et al.
Publicat: (2017)

Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials
per: Cholesterol Treatment Trialists' Collaboration, et al.
Publicat: (2019)

Pharmacogenomics Statins: Biomarkers for Clinical Prediction
per: Herni Suprapti
Publicat: (2018-09-01)

The safety of statins in clinical practice.
per: Armitage, J
Publicat: (2007)

The Genetic Blueprint of Cardiovascular Therapy: Pharmacogenomics for Improved Efficacy and Safety
per: Nikhilesh Andhi, et al.
Publicat: (2024-08-01)

Role of Pharmacogenomics in Statin Responsiveness; A Review
per: Niusha behdad, et al.
Publicat: (2015-12-01)

Role of pharmacogenomics in Statin Responsiveness; A review
per: Niusha behdad, et al.
Publicat: (2015-12-01)

Misrepresentation of statin safety evidence.
per: Armitage, J, et al.
Publicat: (2014)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
per: Hopewell, J, et al.
Publicat: (2011)

Statins: are any questions unanswered?
per: Kearney, P, et al.
Publicat: (2006)

Intensive statin therapy in India: Demonstrating efficacy and safety
per: Michael H. Davidson, MD, FACC, FNLA
Publicat: (2016-11-01)

Moderate-intensity statin therapy. Efficacy and safety issues
per: N. G. Gogolashvili
Publicat: (2023-07-01)

Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry
per: Han Joon Bae, et al.
Publicat: (2020-03-01)

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
per: Reith, CA, et al.
Publicat: (2024)

Pharmacogenomics And Hypertension: Current Insights
per: Oliveira-Paula GH, et al.
Publicat: (2019-11-01)

STATIN GENERICS: EFFICACY AND SAFETY RATIO
per: V. P. Voronina, et al.
Publicat: (2016-01-01)

STATIN GENERICS: EFFICACY AND SAFETY RATIO
per: V. P. Voronina, et al.
Publicat: (2016-01-01)

Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
per: Catarina Correia, et al.
Publicat: (2022-08-01)

Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations
per: Dan Li, et al.
Publicat: (2020-10-01)

Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins
per: Jenna E. van Leeuwen, et al.
Publicat: (2022-10-01)

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
per: Mihaylova, B, et al.
Publicat: (2016)

Efficacy and safety of statin therapy in multimorbid outpatients with very high cardiovascular risk
per: N. V. Izmozherova, et al.
Publicat: (2020-07-01)

Does the benefit from statin therapy extend beyond 5 years?
per: Bulbulia, R, et al.
Publicat: (2013)

Does the benefit from statin therapy extend beyond 5 years?
per: Bulbulia, R, et al.
Publicat: (2013)

Editorial: Insights in pharmacogenetics and pharmacogenomics: 2023
per: José A. G. Agúndez, et al.
Publicat: (2025-01-01)

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
per: José A. G. Agúndez, et al.
Publicat: (2022-04-01)

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
per: Stojiljkovic Maja, et al.
Publicat: (2012-09-01)

Estimating the efficacy of pharmacogenomics over a lifetime
per: Zhan Ye, et al.
Publicat: (2023-10-01)

Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing.
per: James S Floyd, et al.
Publicat: (2019-01-01)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
per: Hopewell, J, et al.
Publicat: (2009)

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics
per: Wei Zhang, et al.
Publicat: (2008-01-01)

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics
per: Wei Zhang, et al.
Publicat: (2008-02-01)

Individual participant data meta-analysis of new-onset and worsening diabetes mellitus in large-scale randomized double-blind trials of statin therapy
per: Preiss, D, et al.
Publicat: (2022)

The Pharmacogenomics of Anti-Hypertensive Therapy
per: Sandosh Padmanabhan, et al.
Publicat: (2010-06-01)

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
per: Lally J, et al.
Publicat: (2016-11-01)

Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses
per: Hai-Yan He, et al.
Publicat: (2017-04-01)

Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
per: Mihaylova, B, et al.
Publicat: (2024)

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
per: Reith, C
Publicat: (2022)

Clinical efficacy and safety of statins in managing cardiovascular risk
per: Navin K Kapur, et al.
Publicat: (2008-04-01)